EXAS Add to watchlist $104.91 +0.00 (+0.00%) Last updated: Jul 15, 2026 04:25
52-Week Range
$104.91
$83.93 $104.91 $125.89

Fundamentals Overview

Exact Sciences Corporation is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/B 8.29 P/S 6.17

Intrinsic value (DCF)

-26.8% downside vs price

Risk (Beta)

1.44 — higher vol

BullzEye Analysis

Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Sell — 69% confidence Risk: High Volatility — Beta 1.44. Consider smaller position size due to higher beta.

Pressures (Sell):

DCF 26.8% downside vs price · Sentiment weakening (11 downgrades) · Beta 1.44 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$20.03B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$83.93 - $125.89
Volume vs Avg
N/A
Beta
1.44

About

Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon ...
Sector: Healthcare
Headquarters: US
Employees: 6,900
IPO Date: Feb 2001
Beta: 1.44 (More volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: majority downgrades. Current institutional positions: Buy: 8, Equal Weight: 2, Hold: 4, In Line: 1, Market Perform: 1, Neutral: 3, Outperform: 3, Overweight: 7, Sector Perform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $76.77; current price is $104.91. That’s a -26.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
DCF value (model) $76.77 (-26.8% vs price)
PEG (TTM) N/A
P/B (TTM) 8.29
P/S (TTM) 6.17
P/FCF (TTM) 56.13
Liquidity & enterprise
Current Ratio (TTM) 2.23
Quick Ratio (TTM) 1.97
Cash Ratio (TTM) 1.49
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -6.4%
Gross margin (TTM) 69.69%
Operating margin (TTM) -6.17%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for EXAS.

Analyst Sentiment at a Glance

Sentiment Weakening
Buy 8Equal Weight 2Hold 4In Line 1Market Perform 1Neutral 3Outperform 3Overweight 7Sector Perform 1
0 upgrades, 11 downgrades
Consensus Target
$105.00
High Target
$105.00
Low Target
$105.00
Median Target
$105.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Mizuho downgrade Outperform Neutral 2026-01-20
Evercore ISI Group downgrade Outperform In Line 2026-01-05
Stifel downgrade Buy Hold 2025-11-28
Canaccord Genuity downgrade Buy Hold 2025-11-25
Jefferies downgrade Buy Hold 2025-11-24
Benchmark downgrade Buy Hold 2025-11-24
Wells Fargo downgrade Overweight Equal Weight 2025-11-21
William Blair downgrade Outperform Market Perform 2025-11-21
Barclays downgrade Overweight Equal Weight 2025-11-21
Guggenheim downgrade Buy Neutral 2025-11-21
BTIG downgrade Buy Neutral 2025-11-20
Piper Sandler maintain Overweight Overweight 2025-11-11
Wells Fargo maintain Overweight Overweight 2025-11-05
Barclays maintain Overweight Overweight 2025-11-04
BTIG maintain Buy Buy 2025-11-04
Benchmark maintain Buy Buy 2025-11-04
Guggenheim maintain Buy Buy 2025-11-04
Stifel maintain Buy Buy 2025-11-04
Baird maintain Outperform Outperform 2025-11-04
TD Cowen maintain Buy Buy 2025-11-04
BTIG maintain Buy Buy 2025-10-22
Piper Sandler maintain Overweight Overweight 2025-10-08
Evercore ISI Group maintain Outperform Outperform 2025-10-07
Barclays maintain Overweight Overweight 2025-10-02
Craig-Hallum maintain Buy Buy 2025-09-11
BTIG maintain Buy Buy 2025-08-12
Piper Sandler maintain Overweight Overweight 2025-08-11
Evercore ISI Group maintain Outperform Outperform 2025-08-08
RBC Capital maintain Sector Perform Sector Perform 2025-08-07
Barclays maintain Overweight Overweight 2025-08-07